Genomic profiling of ER⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

ABSTRACT: Inhibition of proliferation in estrogen receptor-positive (ER⁺) breast cancers after short-term antiestrogen therapy correlates with long-term patient outcome. We profiled 155 ER⁺/human epidermal growth factor receptor 2-negative (HER2^-) early breast cancers from 143 patients treated with the aromatase inhibitor letrozole for 10 to 21 days before surgery. Twenty-one percent of tumors remained highly proliferative, suggesting that these tumors harbor alterations associated with intrinsic endocrine therapy resistance. Whole-exome sequencing revealed a correlation between 8p11-12 and 11q13 gene amplifications, including FGFR1 and CCND1, respectively, and high Ki67. We corroborated these findings in a separate cohort of serial pretreatment, postne

SUBMITTER: Giltnane JM 

PROVIDER: S-EPMC5723145 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature